Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024
13 mai 2024 07h00 HE
|
Entera Bio Ltd.
JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today...
Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting
16 oct. 2023 08h00 HE
|
Entera Bio Ltd.
JERUSALEM, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, presented...
Rani Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ
25 avr. 2023 08h00 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
11 avr. 2023 08h00 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Celltrion and Rani Therapeutics Partner on Development of Oral Monoclonal Antibody Treatment
09 janv. 2023 08h30 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani Therapeutics to Present at Cantor Fitzgerald Virtual Global Healthcare Conference
23 sept. 2021 16h05 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the...
Rani Therapeutics Reports Second Quarter 2021 Financial Results, Provides Corporate Update
13 sept. 2021 16h05 HE
|
Rani Therapeutics, LLC
- IPO in July 2021 raised $84.3 million in gross proceeds -- Talat Imran Appointed Chief Executive Officer -- Enhanced leadership team with key management and board of directors’ appointments - SAN...
Rani Therapeutics Announces Appointment of Eric Groen as General Counsel
09 sept. 2021 08h00 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on advancing...
Rani Therapeutics Announces Closing of its Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
13 août 2021 16h05 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq:RANI) (“Rani Therapeutics” or “Rani”), a clinical stage biotherapeutics company focused on advancing...
Rani Therapeutics Announces Pricing of Initial Public Offering
30 juil. 2021 08h56 HE
|
Rani Therapeutics, LLC
SAN JOSE, Calif., July 30, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”), a clinical stage biotherapeutics company focused on advancing technologies to...